热门资讯> 正文
MannKind的Afrezza正在接受FDA补充审查
2025-10-13 21:43
- MannKind Corporation (MNKD) announced that the U.S. FDA has accepted the supplemental marketing application seeking approval for Afrezza (insulin human) inhalation powder in children and adolescents living with type 1 or type 2 diabetes.
- The application has been assigned a target action date of May 29, 2026.
- The submission is based on results from the Phase 3 INHALE-1 study.
More on MannKind
- MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
- MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
- MannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 Transcript
- MannKind rises as United Therapeutics exercises option for second inhalational drug
- MannKind to buy scPharmaceuticals to expand its cardiometabolic business
推荐文章
财报前瞻 | 特斯拉Q3营收料重获增长！股价季度内狂涨40%，大行喊话依旧被严重低估
美股机会日报 | 美联储鸽派立场恐生变？沃勒称若10月降息，之后须谨慎行动；诺和诺德、礼来盘前跌约4%
恐慌指数单日飙涨22%！“华尔街一哥”拉响区域银行警报，投资者如何对冲股市波动风险？
海西新药上市时间表顺延
华盛早报 | 恐慌指数飙升！区域银行“坏账”担忧打击美股市场，黄金自2024年初以来涨幅翻倍
美股机会日报 | 50个基点？美联储米兰呼吁大幅降息；蔚来遭遇诉讼，盘前大跌近8%
G20风险监管机构警告：全球加密货币监管存在“重大缺口”
新股暗盘 | 海西新药大涨逾101%！中签一手账面浮盈4375港元
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
